INTRODUCTIONAntifibrinolytic agents such as aminocaproic acid and tranexamic acid (TXA) have been utilized for decades to control peri‐procedural bleeding in cardiac, orthopedic, urologic, and dental procedures and more recently as an adjunct to trauma.TXA has a high affinity for the lysine binding site on plasminogen and this inhibits binding to fibrin, which prevents activation of plasmin and the breakdown of clots. The ability of TXA to strengthen clots and limit hemorrhage was demonstrated in vivo as early as the 1970s, and is now being applied in the trauma setting. The large‐scale, multinational, randomized CRASH‐2 trial showed significantly decreased mortality with the administration of TXA in over 20 000 bleeding trauma patients. Timing is critical, as greater mortality reduction is seen with earlier administration.However, TXA has been implicated in the development of vasoocclusive events, although analysis of CRASH‐2 trial participants indicated no difference in the incidence of vasoocclusive events or related deaths with the administration of TXA over placebo. We describe a bleeding trauma patient who received TXA during air transport to our hospital. Although the patient was hemodynamically stable on arrival, imaging revealed the presence of unusual intra‐cardiac masses.PATIENT PROFILEA 31‐year‐old Caucasian female was involved in a single vehicle rollover.
Journal of Cardiac Surgery – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud